Recombinant LIV-1 (Ladiratuzumab Biosimilar) antibody

Catalog No. ABIN7490985

This anti-LIV-1 (Ladiratuzumab Biosimilar) antibody is a Humanized Monoclonal antibody detecting LIV-1 (Ladiratuzumab Biosimilar) in ELISA. Suitable for Human.

Quick Overview for Recombinant LIV-1 (Ladiratuzumab Biosimilar) antibody (ABIN7490985)

Target: LIV-1 (Ladiratuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This LIV-1 (Ladiratuzumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-LIV-1 (Ladiratuzumab Biosimilar) Antibody

Purpose: Anti-LIV-1 (ladiratuzumab biosimilar) mAb

Characteristics: hLIV22

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Application Details

Application Notes: ELISA 1:5000-10000

Comment:

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute with deionized water

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for LIV-1 (Ladiratuzumab Biosimilar)

Target: LIV-1 (Ladiratuzumab Biosimilar)

Target Type: Biosimilar

Background: Synonyms: LIV1, SLC39A6, ZIP-6

UniProt: Q13433